Other OTC • Healthcare • Biotechnology • DK • USD
Novo Nordisk A/S (NONOF) has a consensus analyst rating of Buy, based on 25 analysts covering the stock. Of those, 18 recommend buying, 4 recommend holding, and 3 recommend selling.
No price target data available.
Be the first to know when stocks drop below their intrinsic value.
